These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9357526)

  • 1. Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide.
    Baures PW; Ojala WH; Costain WJ; Ott MC; Pradhan A; Gleason WB; Mishra RK; Johnson RL
    J Med Chem; 1997 Oct; 40(22):3594-600. PubMed ID: 9357526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide.
    Khalil EM; Ojala WH; Pradhan A; Nair VD; Gleason WB; Mishra RK; Johnson RL
    J Med Chem; 1999 Feb; 42(4):628-37. PubMed ID: 10052970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring alpha,alpha-disubstituted amino acids.
    Evans MC; Pradhan A; Venkatraman S; Ojala WH; Gleason WB; Mishra RK; Johnson RL
    J Med Chem; 1999 Apr; 42(8):1441-7. PubMed ID: 10212130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and dopamine receptor modulating activity of substituted bicyclic thiazolidine lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.
    Khalil EM; Pradhan A; Ojala WH; Gleason WB; Mishra RK; Johnson RL
    J Med Chem; 1999 Jul; 42(15):2977-87. PubMed ID: 10425107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and dopamine receptor modulating activity of 3-substituted gamma-lactam peptidomimetics of L-prolyl-L-leucyl-glycinamide.
    Dolbeare K; Pontoriero GF; Gupta SK; Mishra RK; Johnson RL
    J Med Chem; 2003 Feb; 46(5):727-33. PubMed ID: 12593653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of photoaffinity-labeling ligands of the L-prolyl-L-leucylglycinamide binding site involved in the allosteric modulation of the dopamine receptor.
    Fisher A; Mann A; Verma V; Thomas N; Mishra RK; Johnson RL
    J Med Chem; 2006 Jan; 49(1):307-17. PubMed ID: 16392815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes.
    Srivastava LK; Bajwa SB; Johnson RL; Mishra RK
    J Neurochem; 1988 Mar; 50(3):960-8. PubMed ID: 2892892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of novel pyridine based PLG tripeptidomimetics.
    Saitton S; Del Tredici AL; Saxin M; Stenström T; Kihlberg J; Luthman K
    Org Biomol Chem; 2008 May; 6(9):1647-54. PubMed ID: 18421399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of a PLG tripeptidomimetic based on a pyridine scaffold.
    Saitton S; Del Tredici AL; Mohell N; Vollinga RC; Boström D; Kihlberg J; Luthman K
    J Med Chem; 2004 Dec; 47(26):6595-602. PubMed ID: 15588094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide.
    Ott MC; Mishra RK; Johnson RL
    Brain Res; 1996 Oct; 737(1-2):287-91. PubMed ID: 8930377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and dopamine receptor modulating activity of unsubstituted and substituted triproline analogues of L-prolyl-L-leucyl-glycinamide (PLG).
    Baures PW; Pradhan A; Ojala WH; Gleason WB; Mishra RK; Johnson RL
    Bioorg Med Chem Lett; 1999 Aug; 9(16):2349-52. PubMed ID: 10476867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog.
    Verma V; Mann A; Costain W; Pontoriero G; Castellano JM; Skoblenick K; Gupta SK; Pristupa Z; Niznik HB; Johnson RL; Nair VD; Mishra RK
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1228-36. PubMed ID: 16126839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bicyclic thiazolidine lactam peptidomimetics of the dopamine receptor modulating peptide Pro-Leu-Gly-NH2.
    Subasinghe NL; Bontems RJ; McIntee E; Mishra RK; Johnson RL
    J Med Chem; 1993 Aug; 36(16):2356-61. PubMed ID: 8103113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptor modulation by Pro-Leu-Gly-NH2 analogues possessing cyclic amino acid residues at the C-terminal position.
    Johnson RL; Rajakumar G; Mishra RK
    J Med Chem; 1986 Oct; 29(10):2100-4. PubMed ID: 2876103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-prolyl-L-leucyl-glycinamide analogues--a new class of peptide antihypertensives.
    Rajakumar G; Singh AN; Naas F; Chiu S; Kwan CY; Johnson RL; Mishra RK
    J Hypertens Suppl; 1986 Dec; 4(5):S106-8. PubMed ID: 2883271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel l-prolyl-l-leucylglycinamide (PLG) tripeptidomimetics based on a 2-azanorbornane scaffold as positive allosteric modulators of the D
    Sampaio-Dias IE; Sousa CA; García-Mera X; Ferreira da Costa J; Caamaño O; Rodríguez-Borges JE
    Org Biomol Chem; 2016 Nov; 14(47):11065-11069. PubMed ID: 27830864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease.
    Mandel RJ
    Exp Neurol; 2000 Jan; 161(1):212-9. PubMed ID: 10683287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
    Meshul CK; Kamel D; Moore C; Kay TS; Krentz L
    Exp Neurol; 2002 May; 175(1):257-74. PubMed ID: 12009777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats.
    Castellano JM; Batrynchuk J; Dolbeare K; Verma V; Mann A; Skoblenick KJ; Johnson RL; Mishra RK
    Peptides; 2007 Oct; 28(10):2009-15. PubMed ID: 17766011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.